Hotspots and prospects of esophageal cancer research in China.
10.3760/cma.j.cn441530-20221222-00535
- Author:
Yousheng MAO
1
;
Shu Geng GAO
1
;
Yin LI
1
;
Qi XUE
1
;
Feng LI
1
;
Dong Hui JIN
1
;
Hang YI
1
;
Jie HE
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer,Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Esophageal Neoplasms/surgery*;
Combined Modality Therapy;
Neoadjuvant Therapy/methods*;
Chemoradiotherapy;
Chemotherapy, Adjuvant;
Esophagectomy/methods*
- From:
Chinese Journal of Gastrointestinal Surgery
2023;26(4):307-311
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal cancer is a malignant tumor with a high incidence in China. At pesent, advanced esophageal cancer patients are still frequently encountered. The primary treatment for resectable advanced esophageal cancer is surgery-based multimodality therapy, including preoperative neoadjuvant therapy, such as chemotherapy, chemoradiotherapy or chemotherapy plus immunotherapy, followed by radical esophagectomy with thoraco-abdominal two-field or cervico-thoraco-abdominal three-field lymphadenectomy via minimally invasive approach or thoracotomy. In addition, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy, or immunotherapy may also be administered if suggested by postoperative pathological results. Although the treatment outcome of esophageal cancer has improved significantly in China, many clinical issues remain controversial. In this article, we summarize the current hotspots and important issues of esophageal cancer in China, including prevention and early diagnosis, treatment selection for early esophageal cancer, surgical approach selection, lymphadenectomy method, preoperative neoadjuvant therapy, postoperative adjuvant therapy, and nutritional support treatment.
